By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Prometheus Laboratories Inc. 

5739 Pacific Center Boulevard

San Diego  California  92121-4203  U.S.A.
Phone: 888-423-5227 Fax: 858-824-0896



Company News
Prometheus Laboratories Inc. Release: New Data Show Proleukin (aldesleukin) Improves Patient Outcomes As First-Line Therapy For The Treatment Of Patients With Metastatic Melanoma Or Metastatic Renal Cell Carcinoma 5/15/2015 6:15:44 AM
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Show Extension Of Overall Survival Benefits Beyond Complete And Partial Responders In Metastatic Renal Cell Carcinoma Patients Treated With High-Dose Interleukin-2 (HD IL-2) 5/30/2014 9:02:01 AM
Prometheus Laboratories Inc. Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin-2 in SITC Guidelines for Treatment of Cutaneous Melanoma 10/11/2013 8:40:01 AM
Prometheus Laboratories Inc. Appoints Chief Executive Officer 9/19/2013 7:18:13 AM
Prometheus Laboratories Inc. Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of Proleukin® (Aldesleukin for Injection) and Yervoy® (Ipilimumab) in Patients With Metastatic Melanoma 5/30/2013 10:41:58 AM
Prometheus Laboratories Inc. Presents New Data On Growing IBD Diagnostic Portfolio at Digestive Disease Week 2013 5/23/2013 6:14:46 AM
Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin® (Aldesleukin for Injection) Plus Vemurafenib Therapy in Patients with Metastatic Melanoma 5/9/2013 11:37:13 AM
Prometheus Laboratories Inc. Release: New Data Support Use of PROMETHEUS® Anser™ IFX Assay in Managing Infliximab Treatment Failure Among Inflammatory Bowel Disease Patients 10/22/2012 10:28:35 AM
Prometheus Laboratories Inc. Launches New Monitoring Test to Help Guide Inflammatory Bowel Disease Management 8/1/2012 10:12:01 AM
Clinipace Inc. Selected to Manage Prometheus Laboratories Inc. Oncology Program 7/17/2012 9:56:45 AM